Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Type 1 Diabetes (Juvenile Diabetes) – Pipeline Review, H2 2016’, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes)

The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects

The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbGenomics International, Inc.

Adocia

AiCuris GmbH and Co KG

Alteogen Inc.

Amarantus Bioscience Holdings, Inc.

Ambrx, Inc.

AntriaBio, Inc.

Aphios Corporation

APT Therapeutics, Inc.

Araim Pharmaceuticals, Inc.

Argos Therapeutics, Inc.

Artery Therapeutics, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Athersys, Inc.

Atlantic Bio Sci LLC

Axxam SpA

Beta-Cell NV

Biocon Limited

Biogenomics Limited

BioLineRx, Ltd.

BioLingus AG

BioTherapeutics Inc.

BirchBioMed Inc

Boehringer Ingelheim GmbH

Caladrius Biosciences Inc

Cancer Prevention Pharmaceuticals, Inc.

Carlina Technologies SAS

Compugen Ltd.

ConjuChem, LLC

Daewoong Pharmaceutical Co., Ltd.

Dance Biopharm Inc.

Diabetology (Products) Ltd

DiaMedica Inc.

Diamyd Medical AB

Diasome Pharmaceuticals, Inc.

Dompe Farmaceutici S.p.A.

Eli Lilly and Company

enGene, Inc

Ensol Biosciences Inc.

EpiVax, Inc.

Escape Therapeutics, Inc.

Evotec AG

F. Hoffmann-La Roche Ltd.

Fate Therapeutics, Inc.

Generex Biotechnology Corporation

GeNeuro SA

Geropharm

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Grifols, S.A.

Heptares Therapeutics Limited

Iltoo Pharma

ImmusanT, Inc.

Innopharmax Inc.

Intrexon Corporation

Islet Sciences, Inc.

Johnson & Johnson

Kadimastem Ltd.

Kamada Ltd.

Kasiak Research Private Limited

KPI Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

Lonestar Heart, Inc.

MacroGenics, Inc.

Medestea Research & Production S.p.A.

MedImmune LLC

Medy-Tox Inc.

Merck & Co., Inc.

Meridigen Biotech Co., Ltd.

MidaSol Therapeutics LP

Mitsubishi Tanabe Pharma Corporation

Novo Nordisk A/S

Noxxon Pharma AG

Oramed Pharmaceuticals, Inc.

Orgenesis Inc

OSE Immunotherapeutics

Paras Biopharmaceuticals Finland Oy

Parvus Therapeutics, Inc.

Pathfinder Cell Therapy Inc

Pfizer Inc.

PharmaCyte Biotech, Inc.

PharmaIN Corporation

Prometheon Pharma, LLC

Purzer Pharmaceutical Co., Ltd.

RedHill Biopharma Ltd.

REGiMMUNE Corporation

Sanofi

SEKRIS Biomedical, Inc.

Selecta Biosciences, Inc.

Semma Therapeutics Inc.

Sevion Therapeutics, Inc.

Strongbridge Biopharma plc

Therapix Biosciences Ltd.

Thermalin Diabetes, LLC

Toleranzia AB

Transgene Biotek Limited

UCB SA

Unicyte AG

United Therapeutics Corporation

ViaCyte, Inc.

Visionary Pharmaceuticals, Inc.

XL-protein GmbH

XOMA Corporation

Zensun (Shanghai) Sci & Tech Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Type 1 Diabetes (Juvenile Diabetes) Overview 9

Therapeutics Development 10

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies 12

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes 22

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance 24

Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies 28

Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes 41

Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 44

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 150

Drug Profiles 176

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 566

Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 579

Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 582

Appendix 595

List of Tables

List of Tables

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 35

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 36

Number of Products under Development by Companies, H2 2016 38

Number of Products under Development by Companies, H2 2016 (Contd..1) 39

Number of Products under Development by Companies, H2 2016 (Contd..2) 40

Number of Products under Development by Companies, H2 2016 (Contd..3) 41

Number of Products under Development by Companies, H2 2016 (Contd..4) 42

Number of Products under Development by Companies, H2 2016 (Contd..5) 43

Number of Products under Development by Companies, H2 2016 (Contd..6) 44

Number of Products under Development by Companies, H2 2016 (Contd..7) 45

Number of Products under Development by Companies, H2 2016 (Contd..8) 46

Number of Products under Investigation by Universities/Institutes, H2 2016 47

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 48

Comparative Analysis by Late Stage Development, H2 2016 49

Comparative Analysis by Clinical Stage Development, H2 2016 50

Comparative Analysis by Early Stage Development, H2 2016 51

Comparative Analysis by Unknown Stage Development, H2 2016 52

Products under Development by Companies, H2 2016 53

Products under Development by Companies, H2 2016 (Contd..1) 54

Products under Development by Companies, H2 2016 (Contd..2) 55

Products under Development by Companies, H2 2016 (Contd..3) 56

Products under Development by Companies, H2 2016 (Contd..4) 57

Products under Development by Companies, H2 2016 (Contd..5) 58

Products under Development by Companies, H2 2016 (Contd..6) 59

Products under Development by Companies, H2 2016 (Contd..7) 60

Products under Development by Companies, H2 2016 (Contd..8) 61

Products under Development by Companies, H2 2016 (Contd..9) 62

Products under Development by Companies, H2 2016 (Contd..10) 63

Products under Development by Companies, H2 2016 (Contd..11) 64

Products under Development by Companies, H2 2016 (Contd..12) 65

Products under Investigation by Universities/Institutes, H2 2016 66

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 67

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 68

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AbGenomics International, Inc., H2 2016 69

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Adocia, H2 2016 70

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AiCuris GmbH and Co KG, H2 2016 71

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Alteogen Inc., H2 2016 72

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 73

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ambrx, Inc., H2 2016 74

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AntriaBio, Inc., H2 2016 75

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Aphios Corporation, H2 2016 76

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by APT Therapeutics, Inc., H2 2016 77

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Araim Pharmaceuticals, Inc., H2 2016 78

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Argos Therapeutics, Inc., H2 2016 79

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Artery Therapeutics, Inc., H2 2016 80

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Astellas Pharma Inc., H2 2016 81

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by AstraZeneca Plc, H2 2016 82

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Athersys, Inc., H2 2016 83

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Atlantic Bio Sci LLC, H2 2016 84

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Axxam SpA, H2 2016 85

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Beta-Cell NV, H2 2016 86

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biocon Limited, H2 2016 87

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Biogenomics Limited, H2 2016 88

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLineRx, Ltd., H2 2016 89

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioLingus AG, H2 2016 90

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BioTherapeutics Inc., H2 2016 91

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by BirchBioMed Inc, H2 2016 92

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 93

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Caladrius Biosciences Inc, H2 2016 94

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 95

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Carlina Technologies SAS, H2 2016 96

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Compugen Ltd., H2 2016 97

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ConjuChem, LLC, H2 2016 98

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 99

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dance Biopharm Inc., H2 2016 100

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diabetology (Products) Ltd, H2 2016 101

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by DiaMedica Inc., H2 2016 102

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diamyd Medical AB, H2 2016 103

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 104

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 105

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Eli Lilly and Company, H2 2016 106

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by enGene, Inc, H2 2016 107

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ensol Biosciences Inc., H2 2016 108

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by EpiVax, Inc., H2 2016 109

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Escape Therapeutics, Inc., H2 2016 110

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Evotec AG, H2 2016 111

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 112

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Fate Therapeutics, Inc., H2 2016 113

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Generex Biotechnology Corporation, H2 2016 114

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GeNeuro SA, H2 2016 115

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Geropharm, H2 2016 116

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Gilead Sciences, Inc., H2 2016 117

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by GlaxoSmithKline Plc, H2 2016 118

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Grifols, S.A., H2 2016 119

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Heptares Therapeutics Limited, H2 2016 120

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Iltoo Pharma, H2 2016 121

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ImmusanT, Inc., H2 2016 122

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Innopharmax Inc., H2 2016 123

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Intrexon Corporation, H2 2016 124

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Islet Sciences, Inc., H2 2016 125

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Johnson & Johnson, H2 2016 126

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kadimastem Ltd., H2 2016 127

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kamada Ltd., H2 2016 128

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Kasiak Research Private Limited, H2 2016 129

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by KPI Therapeutics, Inc., H2 2016 130

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 131

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 132

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Lonestar Heart, Inc., H2 2016 133

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MacroGenics, Inc., H2 2016 134

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medestea Research & Production S.p.A., H2 2016 135

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MedImmune LLC, H2 2016 136

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Medy-Tox Inc., H2 2016 137

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Merck & Co., Inc., H2 2016 138

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Meridigen Biotech Co., Ltd., H2 2016 139

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by MidaSol Therapeutics LP, H2 2016 140

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 141

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Novo Nordisk A/S, H2 2016 142

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Noxxon Pharma AG, H2 2016 143

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 144

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Orgenesis Inc, H2 2016 145

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by OSE Immunotherapeutics, H2 2016 146

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 147

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Parvus Therapeutics, Inc., H2 2016 148

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pathfinder Cell Therapy Inc, H2 2016 149

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Pfizer Inc., H2 2016 150

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaCyte Biotech, Inc., H2 2016 151

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by PharmaIN Corporation, H2 2016 152

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Prometheon Pharma, LLC, H2 2016 153

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 154

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by RedHill Biopharma Ltd., H2 2016 155

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by REGiMMUNE Corporation, H2 2016 156

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sanofi, H2 2016 157

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by SEKRIS Biomedical, Inc., H2 2016 158

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Selecta Biosciences, Inc., H2 2016 159

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Semma Therapeutics Inc., H2 2016 160

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Sevion Therapeutics, Inc., H2 2016 161

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Strongbridge Biopharma plc , H2 2016 162

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Therapix Biosciences Ltd., H2 2016 163

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Thermalin Diabetes, LLC, H2 2016 164

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Toleranzia AB, H2 2016 165

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Transgene Biotek Limited, H2 2016 166

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by UCB SA, H2 2016 167

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Unicyte AG, H2 2016 168

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by United Therapeutics Corporation, H2 2016 169

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by ViaCyte, Inc., H2 2016 170

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Visionary Pharmaceuticals, Inc., H2 2016 171

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XL-protein GmbH, H2 2016 172

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by XOMA Corporation, H2 2016 173

Type 1 Diabetes (Juvenile Diabetes) – Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016 174

Assessment by Monotherapy Products, H2 2016 175

Assessment by Combination Products, H2 2016 176

Number of Products by Stage and Target, H2 2016 178

Number of Products by Stage and Mechanism of Action, H2 2016 188

Number of Products by Stage and Route of Administration, H2 2016 198

Number of Products by Stage and Molecule Type, H2 2016 200

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects, H2 2016 591

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..1), H2 2016 592

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..2), H2 2016 593

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..3), H2 2016 594

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..4), H2 2016 595

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..5), H2 2016 596

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..6), H2 2016 597

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..7), H2 2016 598

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..8), H2 2016 599

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..9), H2 2016 600

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..10), H2 2016 601

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..11), H2 2016 602

Type 1 Diabetes (Juvenile Diabetes) – Dormant Projects (Contd..12), H2 2016 603

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products, H2 2016 604

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products (Contd..1), H2 2016 605

Type 1 Diabetes (Juvenile Diabetes) – Discontinued Products (Contd..2), H2 2016 606

List of Figures

List of Figures

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2016 35

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2016 36

Number of Products under Development by Companies, H2 2016 37

Number of Products under Investigation by Universities/Institutes, H2 2016 47

Comparative Analysis by Late Stage Development, H2 2016 49

Comparative Analysis by Clinical Stage Development, H2 2016 50

Comparative Analysis by Early Stage Products, H2 2016 51

Assessment by Monotherapy Products, H2 2016 175

Assessment by Combination Products, H2 2016 176

Number of Products by Top 10 Targets, H2 2016 177

Number of Products by Stage and Top 10 Targets, H2 2016 177

Number of Products by Top 10 Mechanism of Actions, H2 2016 187

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 187

Number of Products by Top 10 Routes of Administration, H2 2016 197

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 197

Number of Products by Top 10 Molecule Types, H2 2016 199

Number of Products by Stage and Top 10 Molecule Types, H2 2016 199

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports